Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh

Hassan M. Al-Emran^{1,2†}, Md. Shazid Hasan^{2,3†}, Md. Ali Ahsan Setu², Md. Shaminur Rahman⁴, ASM Rubayet Ul Alam^{2,3}, Shovon Lal Sarkar^{2,3}, Md. Tanvir Islam^{2,3}, Mir Raihanul Islam⁵, Mohammad Mahfuzur Rahman⁶, Ovinu Kibria Islam^{2,3}, Iqbal Kabir Jahid^{2,3*}, M. Anwar Hossain^{2,4,7*}

¹ Department of Biomedical Engineering, Jashore University of Science and Technology, Jashore-7408, Bangladesh

² Genome Centre, Jashore University of Science and Technology, Jashore-7408, Bangladesh

³ Department of Microbiology, Jashore University of Science and Technology, Jashore-7408, Bangladesh

⁴ Department of Microbiology, University of Dhaka, Dhaka-1000, Bangladesh

⁵ Poverty, Health, and Nutrition Division, International Food Policy Research Institute, Dhaka, Bangladesh

⁶ Department of Environmental Science and Technology, Jashore University of Science and Technology, Jashore-7408, Bangladesh

⁷ Vice-Chancellor, Jashore University of Science and Technology, Jashore-7408, Bangladesh

† Both authors share the first authorship.

* Both authors share the senior authorship.

*Corresponding Authors:

M Anwar Hossain, PhD

E-mail: hossaina@du.ac.bd;

Cell: +8801708818101

Iqbal Kabir Jahid, PhD

E-mail: ikjahid_mb@just.edu.bd

Phone: +88-01709-818178; Fax: +88-02421-61199

ABSTRACT

Introduction

Bangladesh introduced ChAdOx1 nCoV-19 since February, 2021 and in six months, only a small population (3.5%) received their first dose of vaccination like other low-income countries. The remaining populations are struggling with increased rate of infection due to beta and delta variants. Although this uncontrolled COVID-19 pandemic did not leave even the immunized group because of immune escaping capacity of those new variants.

Methods

A total of 4718 nasopharyngeal samples were collected from 1st March until 15th April, 2021, of which, 834 (18%) were SARS-CoV-2 positive. Randomly generated 135 positive cases were selected for telephone interview and 108 were available and provided consent. The prevalence of SARS-CoV-2 variants and disease severity among both immunized and unimmunized group was measured. A total of 63 spike protein sequence and 14 whole genome sequences were performed from both groups and phylogenetic reconstruction and mutation analysis were compared.

Results

A total of 40 respondents (37%, N=108) received single-dose and 2 (2%) received both doses of ChAdOx1 nCoV-19 vaccine which significantly reduce dry cough, loss of appetite and difficulties in breathing compared to none. There was no significant difference in hospitalization, duration of hospitalization or reduction of other symptoms like running nose, muscle pain, shortness of breathing or generalized weakness between immunized and unimmunized group. Spike protein sequence assumed 21 (87.5%) B.1.351, one B.1.526 and two 20B variants in immunized group compared to 27 (69%) B.1.351, 5 (13%) B.1.1.7, 4 (10%) 20B, 2 B.1.526 and one B.1.427 variant in unimmunized group. Those variants were further confirmed by 14 whole genome sequence analysis. Complete genome analysis included seven B.1.351 Beta V2, three B.1.1.7 Alpha V1, one B.1.526 Eta and rest three 20B variant.

Conclusion

Single dose of ChAdOx1 couldn't prevent the new infection or disease severity by the COVID-19 variants of concern, B.1.351, in Bangladesh.

INTRODUCTION:

COVID-19 pandemic continued at a cost of 4.2 million deaths from December 2019 until July 2021. Oxford-AstraZeneca (ChAdOx1 nCoV-19), Pfizer-BioNTech (BNT162b2), Johnson & Johnson (Ad26.COV2.S), Sputnik V (Gam-COVID-Vac) and few other COVID-19 vaccines were administered in different countries. Those vaccines are claiming 67%-100% efficacy in preventing COVID-19 clinical cases [1,2]. Although continuous emergence of new variants introduced debates in preventing the disease. In Bangladesh, the Directorate General of Health Services, announced a total of 3,227,598 samples were tested, of which, 513,510 were positive and 7,559 (1.47%) died (<https://corona.gov.bd/storage/press-releases/December2020/KsvQiLw3eIdbv2GTq8RR.pdf>) until December 2020. In 2021 until August, the number of tests increased into more than double (N=7,790,423) with 1,264,328 SARS-CoV-2 positive cases and 20,916 deaths (1.67%) (<http://dashboard.dghs.gov.bd/webportal/pages/covid19.php>). The increased death-case ratio attributed due to B.1351 [3] and B.1.617.2 [4] variants. However, the number was substantially underestimated due to limited transportation towards the diagnostic facilities in many regional parts of Bangladesh. Before the second wave of the pandemic, Bangladesh has introduced ChAdOx1 nCoV-19 and until 4th of August, only 2.7% received two doses and 3.1% received one dose of vaccination, (https://ourworldindata.org/covid-vaccinations?country=OWID_WRL). Therefore, a large proportion of the population remain unimmunized or received only the first dose of ChAdOx1 nCoV-19 vaccine in Bangladesh. Almost 2.5 billion doses of different vaccines have been distributed among 21% of the global population although only 0.8% population in low-income countries received only one dose of a vaccine (https://ourworldindata.org/covid-vaccinations?country=OWID_WRL). Several studies have been performed to evaluate the safety and efficacy of first doses vaccines [5]. First dose of the ChAdOx1 nCoV-19 was found to be effective against 63.9% of symptomatic and asymptomatic cases [5]. In another randomised controlled trials, one standard dose participants showed 64.1% vaccine efficacy [1]. Bernal et al.(2021) reported that first dose ChAdOx1-S effectiveness reached 60% from 28-34 days with further increases to 73% from 35 days to onward for B.1.1.7 variant [6].

A large number of people are being reported to be infected with SARS-CoV-2 during this interim period with those immune-escape variants. Continuous genetic surveillance would assist to reveal those new variants capable of escaping the current immunization. This study emphasized on the infected cases after immunization and analyze the variants of SARS-CoV-2.

METHOD:

Ethical Approval

This study is approved by the ERC of Jashore University of Science and Technology (ERC no: ERC/FBST/JUST/2020-51). Verbal consent was taken from all participants after reading the purpose and objectives. Positive respondents were then asked for a telephone interview with the study questionnaire and enroll the respondent in this study.

Study population

This study was conducted from 1st March until 15th April, 2021 in South-West part of Bangladesh. The Genome Centre, Jashore University of Science and Technology, Jashore, Bangladesh is conducting COVID-19 diagnosis and covering four districts (Jashore, Magura, Narail and Jhenaidha) as a part of the national surveillance system approved by DGHS [7].

A total of 4718 nasopharyngeal samples were collected from 3 districts (Jashore, Narail and Magura) and tested for SARS CoV-2. The RNA was released from the samples using QuickExtract^{TM} RNA extraction kit (Lucigen, Wisconsin, USA) following the manufacturer's instruction. Then, 10 µL of each viral RNA extract was amplified by one-step real-time reverse-transcriptase polymerase chain reaction (RT-PCR) using Novel Coronavirus Nucleic Acid Diagnostic Kit (Sansure Biotech Inc., China). A total of 834 (18%, N=4718) samples were identified for the presence of N-gene or orf1b gene with a CT-value <40 and interpreted as SARS-CoV-2 positive according to the manufacturer's instruction. The participants were excluded from the study if they were unable to participate or receive our calls or does not have the vaccine card or have the history of immunological disorder. In this study, we included day-wise random number generated 135 cases (out of 834), of which, only 108 were available for telephone interview with a prior verbal consent. All respondents (n=108) were interviewed with a pre-tested structured questionnaire over the phone. In the case of unavailability of the respondents due to death, first kin attended the interview.

Vaccination status

All the participants were asked about their vaccination status, number of doses and date of vaccination. The vaccination status was confirmed by vaccine card provided by DGHS, Bangladesh (<https://surokkha.gov.bd/vaccine-status>) or the message provided by the DGHS.

Statistical analysis

Descriptive analysis was conducted using frequency distribution to explore the sociodemographic profile, COVID-19 related experience and information about hospitalization. Chi-square test of independence was performed to explore the relationship between vaccination status and respondents' characteristics. In terms of smaller sample size, fisher exact tests were used to determine the association between the outcome and disaggregated variable.

Spike protein sequencing

RNA was extracted from 140 µl of left-over samples using the QIAamp Viral RNA Mini Kits (QIAGEN, USA) according to the manufacturer protocol. PCR was performed with 7µl of RNA extract using the Luna® Universal One-Step RT-qPCR Kit (New England Biolabs Inc., USA) with the primers for Rbd region of the spike portion of the genome. The details of the protocol were shown in the supplementary Table S1 [8]. The amplicons, confirmed in 1% (w/v) agarose, were sequenced using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystem, ThermoFisher Scientific, Inc., USA). The sequenced FASTA files were initially cleaned with Chromas Pro (<https://technelysium.com.au/wp/>) and aligned with the reference sequence (NC_045512.2/SARS-CoV-2/Wuhan-Hu-1) using Molecular Evolutionary Genetics Analysis (MEGA X) software [9] to detect the presence of any mutations.

Spatial distribution mapping

Spatial distribution of COVID-19 cases was mapped using the ArcGIS (version 10.6) software [10]. The nearest geolocations of the COVID-19 cases were approximated with the help of Google Earth Pro platform (a freely available google product, formerly known as Keyhole Earth Viewer) and as per the description of the respondents.

Whole genome sequencing

First-strand cDNAs were prepared from the extracted viral RNA using SuperScript™ III First-Strand Synthesis System (Invitrogen™, Thermo Fisher Scientific, USA). The concentrations of cDNA were determined using the dsDNA HS Assay Kit with Qubit 4 Fluorometer (Thermo Fisher Scientific, USA). The Ion AmpliSeq™ SARS-CoV-2 Research Panel (Thermo Fisher Scientific, USA) was used to prepare Ion AmpliSeq™ libraries. Two 5X primer pools that target 237 amplicons specific to the SARS-CoV-2 was used during target amplification PCR and number of amplification cycles was determined based on their viral copy number. Each amplified samples

were subjected to 2 μ L FuPa reagents for partial digestion. Digested amplicons were ligated with P1 adapter and Barcode Adapters (Ion Torrent™, Thermo Fisher Scientific, USA). Magnetic bead cleanup was performed using Agencourt™ AMPure™ XP Reagent (Beckman Coulter, USA) to purify barcoded Ion AmpliSeq™ libraries. The library concentration was calculated using Ion Library TaqMan® Quantitation Kit and diluted into 100 picomolar (pM) according to the manufacturer's protocol. All equimolar libraries were pooled for the preparation of template-positive Ion Sphere™ Particles (ISPs) using the Ion 530™ Kit – OT2 (Thermo Fisher Scientific, USA) on the Ion One Touch™ 2 System. Template-positive ISPs were enriched on Ion One Touch™ ES system and loaded in Ion 530™ chip with control ISPs for sequencing into Ion S5™ System.

SARS-CoV-2 Genome consensus generation

Short read of Binary Alignment Map files were converted to Fastq file by using SAMtools v1.12 [11] and the quality checked by using FastQC 0.11.9 [12]. Trimmomatic v0.39 [13] was used to trimmed low quality read (phred score less than 20) and consensus were generated by using Burrows-Wheeler Aligner (BWA v0.7.17) [14], SAMtools v1.12 [11] and BEDTools v2.30.0 [15] by aligning a reference genome (hCoV-19/Wuhan/WIV04 (GenBank accession no. MN996528.1). Further indel and area wise mutation coverage were checked by using Snippy [16] and corrected the read.

Phylogenetic reconstruction and mutation analysis

Nextstrain SARS-CoV-2 phylogenetic tree generation pipeline (<https://nextstrain.org/sars-cov-2>) has been used to reconstruct the phylogenetic tree with Nextstrain clade of the sequenced (n=14) [17]. Nextstrain uses MAFFT [18] as an alignment tools, IQ-TREE [19] and TreeTime [20] to reconstruct tree and Auspice web server (<https://auspice.us/>) to visualize the tree. Mutations and clades have assigned from CoVserver mutation app (<https://www.gisaid.org/epiflu-applications/covserver-mutations-app/>) of Global initiative on sharing all influenza data (GISAID) where hCoV-19/Wuhan/WIV04 (GenBank accession no. MN996528.1) was used as a reference genome. Heatmap with nonsynonymous mutations was generated by using an R package Pheatmap [21] and violin plot of between synonymous and nonsynonymous mutations was generated by using ggplot2 [22]. The Pearson correlation coefficient was measured between the immunized and unimmunized group.

RESULTS:

Description of study population

This study reports information of 108 COVID-19 positive cases tested between March 1 to April 15, 2021. The socio-demographic profiles, co-morbidity, vaccination and COVID-19 associated symptoms, diagnosis and treatment information of the studied population are presented in Table 1. Studied respondents were dominated by males (75%) and were mainly from aged group 50-60 years (34%) followed by 40-50 years (28%). The mean age of the respondents were 50 years (maximum 76.4, minimum 14.4 and median 50.5 years). Estimated Body Mass Index (BMI) suggests that half of the studied respondents can be characterized as either overweight (40.7%) or obese (10.2%). Majority of the respondents (66.4%) completed their secondary or higher education, whereas 14% of them didn't complete their primary education. Occupationally, they were engaged in service or business (60.2%) homemaker (18.5%) and unemployed or retired (13.0%).

The study reported several co-morbidities among half of the respondents. Most often the respondents reported high blood pressure (31.5%) followed by diabetes (26%), cardiac diseases (9.3%) and asthma (4.6%) etc. Majority of the respondents suffered from fever (61%), dry cough (43.5%), loss of smell (26%), loss of taste (24%) and muscle pain (22%) during the infection. The respondents approached for a COVID-19 test due to their generalized sickness (79.6%), exposure with COVID-19 patient (8.3%) and other reasons (12%). About 63% respondents reported a complete recovery, while 30.6% were still suffering (generalized weakness, emotional changes, and dementia) and 6.5% died (Table S2). About 39% (n = 42) of the respondents were infected after the COVID-19 vaccination. First dose of ChAdOx1 nCoV-19 vaccine was received by 40 (37.0%) cases and both doses were completed by only 2 (2%) cases. The average duration between vaccination (partially or completely immunized) and COVID 19 diagnosis was 32(±17) days. Almost 86% and 69% of the respondents were infected minimum after 2 and 3 weeks of administration of first dose, respectively (Figure 1). Among the respondents, 15.7% (n = 17) suffered from severe consequences and required hospitalization for 1 to 17 days (mean 7.72 days and median 6 days). Additional oxygen was supplemented to 13% (N=14) of the respondents during their hospitalization, of them, 7 respondents (6.5%) were shifted to Intensive care unit (ICU) and 4 died. Three respondents died at home before rushing towards the hospital.

We performed the comparative analysis of vaccination status and respondents' characteristics (Table 1). We have disaggregated the analysis in two sections, section I considering all age groups, section II considering only 16 to 70 years old respondents. In all age group, we observe that education status has significant relationship with the vaccination status. Most of respondents (83.3%) immunized group completed their secondary or higher education. Difficulty of breathing and loss of appetite were significantly higher in the unimmunized group (27% vs. 7%, and 23% vs. 7%, respectively, $p < 0.05$) which was also found among 16-70 years. Dry cough was also significantly high in all ages among unimmunized group ($p < 0.05$). Fever was more common among in that group although not significant ($p = 0.067$). Apparently, in our study we couldn't found any significant difference of hospitalization ($p = 0.383$) (Figure S1) and duration of hospitalization ($p = 0.780$). Hospitalization rate of comorbid patients were also similar (24% both) between both groups (Table S3). Additionally, we compared the mean CT values of immunized and unimmunized patients, where we identified a significant increase of *N*-genes ($p = 0.026$) and Orf-1b gene ($p = 0.052$) among unimmunized (Figure S2).

Spatial distribution of identified COVID-19 variants

The spatial distribution of COVID-19 variants suggested a clear clustering and localized proliferation (Figure 2). South African variants (B.1.351) showed prominent clusters and, thus results localized hotspots in the Jashore Municipality.

Spike protein variants

In this study, only 78 samples had the threshold cycle (CT value) below 35 in RT-PCR screening test and considered as potential candidate for partial or complete genome sequencing, of which, only 76 left-over samples were available. The concentration of spike protein RNA might be low in rest 13 samples and could not be visualized in gel electrophoresis. The template RNA provided 850bp spike protein amplicons in 63 patients' samples, of which, 24 patients were partially or completely immunized before the COVID-19 infection. Spike protein sequence mutation analysis revealed that 21 (87.5%) strains might be B.1.351 variant, one was B.1.526 variant and two were conventional without any mutation. Among the unimmunized 39 viral strains, spike protein sequences analysis suspected 27 (69%) B.1.351, 5 (13%) B.1.1.7, 4 (10%) conventional, 2 B.1.526 and one B.1.427 variant. Figure 2 showed the spatial distribution of 63 SARS-CoV-2 variants among both groups, rest 45 out of 108 were marked as unknown in the map. Most cases (N=95)

were detected from the largest district, Jashore. Few other cases were located in Magura (N=10) and Narail (N=3). Mutation analysis revealed that 16% (10 out of 63) of the strains had non-synonymous unique mutations in their RBD region of the spike protein; 7 (18%, n=39) of which belongs to unimmunized groups and 3 (12.5%, n=24) belong to immunized group. Three B.1.351 variants and 2 B.1.526 variants each contain single unique mutation and two others B.1.351 variants contain multiple unique mutation among unimmunized group (Table 2). Compared to that, immunized group contain F515S mutation in two and W353R in one B.1.351 variant.

Complete genome and mutation analysis

The complete genome of SARS-CoV-2 analyzed to map a radial phylogenetic tree (Figure 3) and it has found that six different variants for both immunized and unimmunized groups (Table 2 and Table S4). Complete genome analysis (n = 14) included 7 B.1.351 Beta V2 variant, 3 B.1.1.7 Alpha V1 variant, one B.1.526 Eta variant and rest three 20B variant (Figure 4) from both groups. The t-test found a non-significant difference between the mean frequency of synonymous (p=0.396) and non-synonymous (p=0.083) mutations between the immunized and unimmunized group (Figure 5). N501Y mutation was found in 9 strains; 3 harbored in partially immunized patients and 6 harbored in unimmunized patients. P681H mutation were possessed by 3 strains and all were belonged to unimmunized patients. H69–V70 deletion found in 3 strains (2 unimmunized, 1 partially immunized patients) and Y144 deletion found in 2 strains (1 unimmunized, 1 partially immunized patients). E484K mutation was possessed by 7 (50%) strains among which 4 patients were partially immunized and 3 patients were unimmunized. K417N mutation was found in 4 partially immunized patients and 2 unimmunized patients. L452R substitution is found in 2 strains (Figure 4).

DISCUSSION:

Emergence of SARS-CoV-2 variants is a global problem during COVID-19 pandemic [23–26]. Those variants has been designated as variants of interest (VOI) and variants of concern (VOC) by WHO (<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>) and CDC (<https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>) depending on its genetic changes that affects transmissibility, disease severity, immune escape, diagnostic or therapeutic escape, increasing prevalence, increasing virulence, decreasing the effectiveness of vaccines etc.

This study found that first or second dose of ChAdOx1 did not prevent the new infections by the variants of interests and variants of concern (B. 1.526, B.1.351, and 20B) in Bangladesh except the B.1.1.7 variant. Most of the viruses (87.5%) detected from the vaccinated patients were identified as B.1.351 variant indicating that the ChAdOx1 couldn't prevent new infection by this variant of concern (Table 2). The SARS-CoV-2 variants and the efficacy of the different vaccines has been reviewed by Bian et al. (2021) [27] and demonstrated that efficacy was reduced from ranges 0.78 to 9. The highest reduction was 9.0 observed for B.1.351 variant of ChAdOx1 [28]. Madhi et al. also noted that ChAdOx1 vaccine efficacy was only 10.4% after two doses in South Africa where B.1.351 was predominant [29]. Few studies found the similar results that the ChAdOx1 vaccine are not effective against recent variant of concerns such as B.1.617.2 [6] and Delta 1 [30]. That raised a dubious situation about the efficacy COVID-19 vaccine among the population [31].

A study in Argentina, Brazil Chile, Colombia, Mexico, Peru, South Africa and the United States found that single dose ChAdOx1 vaccine efficacy was 52 to 64% [32]. Few studies claimed that single dose vaccination protect from infections including B.1.1.7 [6,33–35]. However, in our study, most of the COVID-19 infections (71%, N=30) were identified after 3rd weeks of vaccine administration, with a mean duration of 32(±17) days (Figure 1). Even after 4th week (52%, N=22) of vaccination the antibody couldn't prevent new infection by SARS-CoV-2 B.1.351 variant. A study by Tauzin et al. reported that BNT162b2 vaccine was 90% effective after 3 weeks by the production of g anti-receptor binding domain and spike antibodies with Fc-mediated effector functions and cellular CD4+ T cell responses [36].

However, Madhi et al. observed that ChAdOx1 vaccine couldn't offer any protection against low and mild infection of SARS-CoV-2 due to B.1.351 variant [29]. In our study, we found that the ChAdOx1 vaccine significantly reduce dry cough, loss of appetite and difficulties in breathing. However, there was no significant reduction of other symptoms like, running nose, muscle pain, shortness of breathing, generalized weakness, emotional changes etc (Table 1). Madhi et al couldn't include any hospitalized cases to observe the effect on severe cases. Our study found no significant differences in disease severity in terms of hospitalization ($p=0.383$) (Figure S1) or the duration of hospitalization ($p=0.780$) when compared between the immunized and unimmunized group. Another previous study by Bernal et al. [6] reported 37% reduction of hospitalization in case of single dose vaccination by ChAdOx1, although we found only 6.3% reduction (Table 1).

SARS-CoV-2 infected patients comorbidity affected by diabetes, asthma or high blood pressure were facing the severe consequences throughout the pandemic. Previous studies found 28-50% of hospitalization among comorbid patients from January to March 2020 [37]. The rate of hospitalization of comorbid patients in our study was 23.5% among the immunized and 24.1% among the nonimmunized groups (Table S3). In another study observed that one dose vaccination with either BNT162b2 or ChAdOx1 nCoV-19 could reduce the hospitalization rate by 51% among the elderly group aged above 80 [38].

Although there was no significant difference in hospitalization and comorbid groups, the RT-PCR results found a significant difference in threshold cycles values (Figure S2) of immunized and unimmunized groups ($p=0.026$ for N-gene, $p=0.052$ for ORF1b gene). A previous study also found the similar results [39] without any correlation of the vaccine efficacy or disease severity and outcomes. However, Pritchard et al showed significant difference of Ct values with reduction of symptomatic infections, hospitalization and death [34].

There were no significant differences found in the number of the synonymous and non-synonymous mutations on the whole genome sequences of viruses collected from immunized and unimmunized patients, even though higher numbers of mutations were observed for unimmunized groups (Figure 5). The unimmunized groups showed more unique mutations in spike protein as well as in other positions. Important mutations that can play vital roles in evading immune responses are the characteristic of variant of concerns. In our study we found those mutations in both immunized and unimmunized groups. Asparagine to tyrosine conversion at 501 amino acid position (N501Y) of spike glycoprotein helps the virus latch on more tightly to human cells. But the mutation is not likely to help the virus evade current vaccines [40]. This mutation harbored in 3 partially immunized patients and 6 unimmunized patients. Proline to Histidine substitution (P681H) at spike glycoprotein may help infected cells create new spike proteins more efficiently (Jonathan Corum, 2021) which was found 3 unimmunized patients in our study. The histidine and valine deletion from 69 and 70 positions (H69–V70) and tyrosine deletion from 144/145 position (Y144/145) in spike glycoprotein alter the shape of the spike and may help it evade some antibodies [40]. H69–V70 deletion found among 3 patients (2 unimmunized, 1 partially immunized) and Y144 deletion found among 2 patients (one in each group). Lysine to asparagine alteration at 417 position (K417N) of spike glycoprotein helps the virus bind more tightly to human

cells [40]. This mutation was found in 6 study patients (4 in immunized and 2 in unimmunized patients). E484K substitution may help the virus evade antibodies [40] which was found 4 immunized and 3 unimmunized patients. L452R substitution is common in B.1.427, but not yet shown to be more infectious (Figure 4).

Bangladesh had started pilot vaccination program with ChAdOx1 on January 27, 2021 and nationwide vaccination program started on February 7. This study investigated to observe the variants after the selective pressure with first dose of vaccination in the population (Figure 2) and the samples were collected from 1st March to 15th April, 2021. During that time Bangladesh was facing the second wave of SARS-CoV-2 infection in which Variant B.1.351 was found predominant [24]. The study was conducted before the first case of B.1.617.2 variant were reported in Bangladesh by our research group [41]. Whole genome sequencing is an expensive and time-consuming process; thus, it was not suitable for large-scale variant surveillance in countries with limited research funding like Bangladesh. The possibility and necessity of detecting important mutations by partial sequencing of the viral genome was mentioned by our research group [8,42]. Detection of the ‘signature mutations’ in spike proteins by Sanger sequencing can be useful for the initial screening of the variants. This initial data can be verified by performing whole genome sequences considering the virus type, pathology and itinerary of the infected patient. In this study we applied both partial sequencing and whole genome sequencing for variant screening (Table 2 and Figure 3). Although this study is limited to low number of participants, thus it can provide only a little update on SARS-CoV2 variant profile during the vaccination program in Bangladesh.

This is the first report from Bangladesh about the post vaccination variants during the second wave of pandemic by B.1.351 that provided the impact of selective pressure in the community after the first dose of vaccination. The continuous monitoring of variants is essential considering the large number of populations might receive only single dose for a while and there are limited supplies of this most demanding vaccine. The impact of vaccination should be carefully measured because a large number of populations are getting infected during the interim period between two doses. Those, who get infected with COVID-19 after the first dose of vaccination, might be kept in the least priority list, rather offering new personnel who neither receive any dose nor was recently infected. WHO shall also make a suggestion or guideline for the recently infected personnel regarding the minimum time gap between active infection and next dose of vaccine.

References

- [1] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021;397:99–111.
- [2] Rossman H, Shilo S, Meir T, Gorfine M, Shalit U, Segal E. COVID-19 dynamics after a national immunization program in Israel. *Nat Med* 2021;27:1055–61.
<https://doi.org/10.1038/s41591-021-01337-2>.
- [3] Rahman M, Shirin T, Rahman S, Rahman MM, Hossain ME, Khan MH, et al. The emergence of SARS-CoV-2 variants in Dhaka city, Bangladesh. *Transbound Emerg Dis* 2021.
- [4] Moona AA, Daria S, Asaduzzaman M, Islam MR. Bangladesh reported delta variant of coronavirus among its citizen: Actionable items to tackle the potential massive third wave. *Infect Prev Pract* 2021.
- [5] Hung IFN, Poland GA. Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster. *Lancet* 2021;397:854–5.
- [6] Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *Bmj* 2021;373.
- [7] DGHS. Coronavirus COVID-19 Dashboard 2021.
- [8] Islam MT, Alam ASMRU, Sakib N, Hasan MS, Chakrovarty T, Tawyabur M, et al. A rapid and cost-effective multiplex ARMS-PCR method for the simultaneous genotyping of the circulating SARS-CoV-2 phylogenetic clades. *J Med Virol* 2021.
<https://doi.org/10.1002/jmv.26818>.
- [9] Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. *Mol Biol Evol* 2018;35:1547.
- [10] Porter SA, Tomer MD, James DE, Boomer KMB. *Agricultural Conservation Planning*

Framework ArcGIS ® Toolbox User ' s Manual n.d.:1–72.

- [11] Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. *Bioinformatics* 2009;25:2078–9.
- [12] Andrews S. Babraham bioinformatics-FastQC a quality control tool for high throughput sequence data. URL <https://www.bioinformatics.babraham.ac.uk/projects/fastqc> 2010.
- [13] Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 2014;30:2114–20.
- [14] Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics* 2009;25:1754–60.
- [15] Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* 2010;26:841–2.
- [16] Seemann T. Snippy: rapid haploid variant calling and core SNP phylogeny. GitHub Available at: [Github Com/Tseemann/Snippy](https://github.com/Tseemann/Snippy) 2015.
- [17] Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* 2018;34:4121–3.
- [18] Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol* 2013;30:772–80.
- [19] Nguyen L-T, Schmidt HA, Von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol* 2015;32:268–74.
- [20] Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic analysis. *Virus Evol* 2018;4:vex042.
- [21] Kolde R, Kolde MR. Package ‘pheatmap.’ *R Packag* 2015;1:790.
- [22] Wickham H. ggplot2. *Wiley Interdiscip Rev Comput Stat* 2011;3:180–5.
- [23] Islam OK, Al-Emran HM, Hasan MS, Anwar A, Jahid MIK, Hossain MA. Emergence of European and North American mutant variants of SARS-CoV-2 in South-East Asia.

- Transbound Emerg Dis 2021;68:824–32. <https://doi.org/10.1111/tbed.13748>.
- [24] Saha S, Tanmoy AM, Hooda Y, Tanni AA, Goswami S, Sium SM Al, et al. COVID-19 rise in Bangladesh correlates with increasing detection of B.1.351 variant. *BMJ Glob Heal* 2021;6. <https://doi.org/10.1136/bmjgh-2021-006012>.
  - [25] IEDCR Report. Delta variant dominant in recent Covid-19 cases: IEDCR. *Dly Star Digit* 2021.
  - [26] Alam ASMRU, Islam OK, Hasan MS, Islam MR, Mahmud S, AlEmran HM, et al. Evolving Infection Paradox of SARS-CoV-2: Fitness Costs Virulence? *MedRxiv* 2021.
  - [27] Bian L, Gao F, Zhang J, He Q, Mao Q, Xu M, et al. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. *Expert Rev Vaccines* 2021. <https://doi.org/10.1080/14760584.2021.1903879>.
  - [28] Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera. *Cell* 2021;184:2348-2361. e6.
  - [29] Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med* 2021;384:1885–98. <https://doi.org/10.1056/nejmoa2102214>.
  - [30] Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Antibody evasion by the Brazilian P. 1 strain of SARS-CoV-2. *BioRxiv* 2021.
  - [31] Karim SSA. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. *Lancet* 2021;397:1263–4. [https://doi.org/10.1016/S0140-6736\(21\)00468-2](https://doi.org/10.1016/S0140-6736(21)00468-2).
  - [32] Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. *N Engl J Med* 2021;384:2187–201.
  - [33] Lumley SF, Rodger G, Constantinides B, Sanderson N, Chau KK, Street TL, et al. An observational cohort study on the incidence of SARS-CoV-2 infection and B. 1.1. 7 variant infection in healthcare workers by antibody and vaccination status. *MedRxiv* 2021.

- [34] Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta KD, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. *Nat Med* 2021.
<https://doi.org/10.1038/s41591-021-01410-w>.
- [35] Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. *Lancet Infect Dis* 2021.
- [36] Tauzin A, Nayrac M, Benlarbi M, Gong SY, Gasser R, Beaudoin-Bussires G, et al. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. *Cell Host Microbe* 2021.
<https://doi.org/10.1016/j.chom.2021.06.001>.
- [37] Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. *SN Compr Clin Med* 2020:1–8.
- [38] Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. *Lancet Infect Dis* 2021.
- [39] Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. *Nat Med* 2021;27:790–2.
- [40] Jonathan Corum CZ. *Coronavirus Variants and Mutations* 2021.
- [41] Md. Shazid Hasan, Md. Tanvir Islam, A. S. M. Rubayet Ul Alam, Shovon Lal Sarkar, M. Shaminur Rahman, Ovinu Kibria Islam, Md. Ali Ahsan Setu, Tanay Chakrovarty, Hassan M. Al-Emran, Iqbal Kabir Jahid MAH. Initial reports of the SARS-CoV-2 Indian B.1.617.2 lineage in Bangladeshi patients: risks of cross-border leakage/transmission from India. *Heal Sci Reports* 2021.
- [42] ASMRU A, MR I, MS R, OK I, MA H. Understanding the possible origin and genotyping of the first Bangladeshi SARS-CoV-2 strain. *J Med Virol* 2021;93:1–4.

Acknowledgments: We would like to acknowledge the Genome Center, Jashore University of Science and Technology, to provide the laboratory facilities to perform this study.

Funding: The study was funded (JUST/Research Cell/Research Project/2020-21/FOET11) by Jashore University of Science and Technology, Jashore-7408, Bangladesh.

Conflicts of interest: All authors declare no competing interests in this study.

Data availability statement: The whole genome sequence data analysed in this study were deposited in GISAID (<https://www.gisaid.org/>) with accession no. mentioned in Table S4.

Authors contributions

HMA: Conceptualization, methodology, validation, formal analysis, investigation, visualization, writing original draft, funding acquisition.

MSH: Methodology, investigation, resources, validation, writing original draft.

MAAS: Investigation, analysis, data curation.

SR: Software, Formal analysis, data curation.

ASMRA: writing review and editing, resources

SLS: Investigation, analysis, data curation.

MTI: writing review and editing.

MRI: Data analysis, writing review and editing.

MMR: GPS mapping, data analysis, writing review and editing.

OKI: Software, formal analysis, writing review and editing, resources.

IKJ: formal analysis, validation, writing review and editing, resources, supervision, project administration.

MAH: writing review and editing, supervision, project administration.

Table 1: Statistical analysis of the study patients' profile.

Table 2: Identification of SARS-CoV-2 variants and their non-synonymous unique mutations.

Figure 1: Duration between SARS-CoV-2 infection and first dose of immunization. 86% (N=36) of the cases were infected after 14 days and 71% (N=30) of them were infected after 21 days of vaccination. Red dots represent the death cases and black dots represent the survived cases.

Figure 2: Geospatial location of SARS-CoV-2 variants. Red marks indicate the unimmunized SARS-CoV-2 infected patients. Blue marks indicate the partial or complete immunized COVID-19 patients.

Figure 3: Phylogenetic of tree with their existing clade with world reference genome. Red color represents unimmunized variants, sky-blue represents partially immunized and orange color represents completely immunized variants in the tree.

Figure 4: Comparison of amino acid substitutions retrieved from genome sequences of SARS-CoV-2 viruses among immunized and unimmunized patients. Mutations and amino acid substitutions were retrieved from Nextclade (<https://clades.nextstrain.org/>).

Figure 5: Synonymous ($p=0.396$) and non-synonymous ($p=0.083$) mutation status between immunized and unimmunized patients.

Table 1: Statistical analysis of the study patients’ profile.

Variables	Section I: All ages groups			Section II: 16 to 70 years		
	1st dose	Non immunized	P value	1st dose	Non immunized	P value
	% (n)	% (n)		% (n)	% (n)	
Sociodemographic profile						
Sex						
Male	83.3 (35)	69.7 (46)	0.111	82.5 (33)	70.5 (43)	0.171
Female	16.7 (7)	30.3 (20)		17.5 (7)	29.5 (18)	
BMI						
Normal	45.2 (19)	51.5 (34)	0.777	42.5 (17)	50.8 (31)	0.731
Overweight	45.2 (19)	37.9 (25)		47.5 (19)	39.3 (24)	
Obese	9.5 (4)	9.5 (7)		10.0 (4)	9.9 (6)	
Education						
No education or primary incomplete	4.8 (2)	20.0 (13)	0.009	5.0 (2)	18.0 (11)	0.027
Secondary incomplete	11.9 (5)	24.6 (16)		12.5 (5)	24.6 (15)	
Secondary or higher	83.3 (35)	55.4 (36)		82.5 (33)	57.4 (35)	
Occupation						
Unemployed	14.3 (6)	12.1 (8)	0.223	12.5 (5)	9.8 (6)	0.440
Service/business	69.1 (29)	54.6 (36)		70.0 (28)	59.0 (36)	
Homemaker	14.3 (6)	21.2 (14)		15.0 (6)	21.3 (13)	
Others	2.4 (1)	12.1 (8)		2.5 (1)	9.8 (6)	
Presence of any comorbidities						
Yes	59.5 (25)	43.9 (29)	0.114	60.0 (24)	44.3 (27)	0.122
No	40.5 (17)	56.1 (37)		40.0 (16)	55.7 (34)	
Comorbidities (Multiple response)						
Diabetes	19.1 (8)	30.3 (20)	0.193	17.5 (7)	29.5 (18)	0.171
High blood pressure	31.9 (13)	31.0 (21)	0.925	30.0 (12)	32.8 (20)	0.768
Clinical manifestation						
Symptoms (Multiple response)						
Fever	50.0 (21)	67.7 (44)	0.067	47.5 (19)	66.7 (40)	0.058
Dry cough	31.0 (13)	51.5 (34)	0.036	30.0 (12)	49.2 (30)	0.056
Running nose	7.1 (3)	13.6 (9)	0.361	7.5 (3)	14.8 (9)	0.355
Muscle pain	26.2 (11)	19.7 (13)	0.429	25.0 (10)	19.7 (12)	0.526
Difficulties in breathing	7.1 (3)	27.3 (18)	0.012	7.5 (3)	27.9 (17)	0.012
Loss of smell	19.1 (8)	30.3 (20)	0.193	17.5 (7)	31.2 (19)	0.125
Loss of taste	21.4 (9)	25.8 (17)	0.608	22.5 (9)	27.9 (17)	0.546
Loss of appetite	7.1 (3)	22.7 (15)	0.034	5.0 (2)	23.0 (14)	0.016
Complications after covid 19 positive (Multiple response)						
Generalized weakness	11.9 (5)	18.2 (12)	0.383	12.5 (5)	19.7 (12)	0.346
Emotional changes	7.1 (3)	7.6 (5)	1.000	7.5 (3)	8.2 (5)	1.000
Dementia	9.5 (4)	6.1 (4)	0.709	10.0 (4)	6.6 (4)	0.709
COVID-19 severity						

Hospitalized	11.9 (5)	18.2 (12)	0.383	10.0 (4)	14.8 (9)	0.485
Duration						
No hospitalization	88.1 (37)	81.5 (53)		90 (36)	85 (51)	
1 week	7.1 (3)	10.8 (7)	0.780	7.5 (3)	10 (6)	0.723
More than 1 week	4.8 (2)	7.7 (5)		2.5 (1)	5 (3)	
Oxygen	9.5 (4)	15.2 (10)	0.396	7.5 (3)	14.8 (9)	0.355
Spike protein variants						
Sanger variant						
B.1.351	52.4 (22)	39.4 (26)	0.185	52.5 (21)	39.3 (24)	0.193
B.1.1.7	0.0 (0)	7.6 (5)	0.154	0.0 (0)	4.9 (3)	0.275
B.1.526, B.1.427 and Conventional	7.1 (3)	10.6 (7)	0.737	7.5 (3)	9.8 (6)	1.000
Unknown	42.4 (17)	40.5 (28)	0.841	40.0 (16)	45.9 (28)	0.559

Table 2: Identification of SARS-CoV-2 variants and their non-synonymous unique mutations.

Spike protein sequences				
Variant	Immunized (number of variants)	Unique Mutations (No of strains)	Unimmunized (number of variants)	Unique Mutations (No of strains)
B.1.351	21	F515S (2) W353R (1)	27	-I402N (1) -I402M (1) -G413W (1) -N394K, E406K, D405E, Q414E, S375F (1) -N394K, E406K, Q414E, S375F (1)
B.1.1.7	0		5	
Conventional	2		4	
B.1.427	0		1	
B.1.526	1		2	-F377I (1), -Q414E (1)
Whole genome sequences				
Variant	Immunized (frequency of unique mutation in a single strain)	Average Unique Mutations	Unimmunized (frequency of unique mutation in a single strain)	Average Unique Mutations
B.1.351	11, 22, 19, 21	18.3	20,22,11	17.7
B.1.526	13		22	
B.1.1.7			34	
Conventional/Unrecognized (20B)	7, 13	10	22, 12	17

Table S1: Luna® Universal One-Step RT-qPCR Protocol

PCR mix		
Reaction mix	: 10ul	
RT-enzyme mix	: 1ul	
S_F	: 0.8ul	
S_R	: 1.2ul	
Template	: 7ul	
PCR conditions		
	Temperature	Time
RT	55° C	12 min
Initial denaturation	95° C	1 min
Cycling part (40 cycles):		
Denaturation	95° C	30 sec
Annealing	58° C	45 sec
Extension	60° C	1 min
Final extension	60° C	7.5 min
Hold	4° C	∞
Gel Run		
Gel concentration	: 1% agarose	
Gel volume	: 60ul	
Dye	: Ethidium Bromide	
Ladder	: 50bp , 6-7ul /well	
PCR product	: 5ul/well	
Voltage	: 80 V	
Current	: 150 mA	
Time	: 40 min	

Table S2: Sociodemographic profile and COVID 19 related information

Variables	Percentage (%)	Frequency (n)
Sociodemographic profile		
Age		
Less than 35 years	9.3	10
35 to 60 years	67.6	73
More than 60 years	23.2	25
Sex		
Male	75.0	81
Female	25.0	27
BMI		
Normal	49.1	53
Overweight	40.7	44
Obese	10.2	11
Education		
No education or primary incomplete	14.0	15
Secondary incomplete	19.6	21
Secondary or higher	66.4	71
Occupation		
Unemployed/retired	13.0	14
Service/business	60.2	65
Homemaker	18.5	20
Others	8.3	9
Comorbidities		
Yes	50.0	54
No	50.0	54
If yes, then are the comorbidities (Multiple response)		
Asthma	4.6	5
Diabetes	25.9	28
High blood pressure	31.5	34
Low blood pressure	3.7	4
Cardiac disease	9.3	10
Covid 19 related information		
Sanger variants		
Unknown	41.7	45
UK	5.6	6
South Africa	45.4	49
Conventional and others	7.41	8
Symptoms (Multiple response)		
Fever	60.8	65
Dry cough	43.5	47
Running nose	11.1	12
Muscle pain	22.2	24
Difficulties in breathing	19.4	21

Loss of smell	25.9	28
Loss of taste	24.1	26
Loss of appetite	16.7	18
Headache	7.4	8
Pain or swelling of legs, hands	10.2	11
Diarrhoea	8.3	9
Sore throat	6.5	7
Reason for covid 19 testing		
Sick/hospitalized	79.6	86
Close contact with covid 19 patient	8.3	9
For travel and others	12.0	13
Outcome		
Completely recovered	63.0	68
Still weak	30.6	33
Death	6.5	7
Complications after covid 19 positive (Multiple response)		
Generalized weakness	15.7	17
Emotional changes	7.4	8
Dementia	7.4	8
Vision or changes in eye power	0.9	1
Loss of smell	2.8	3
Loss of taste	3.7	4
Muscle pain	4.6	5
Breathing problem	1.9	2
Vaccination		
Yes	38.9	42
No	61.1	66
Information on hospitalization		
Hospitalized		
Yes	15.7	17
No	84.3	91
Duration		
No hospitalization	84.3	91
1 week	9.3	10
More than 1 week	6.5	7
ICU		
Yes	6.5	7
No	93.5	101
Oxygen		
Yes	13.0	14
No	87.0	94

Table S3: Hospitalization in comorbid patients (including death cases)

	Immunized % (n)	Non-immunized % (n)	p-value
Duration			
Discharged immediately	76.5 (13)	75.7 (28)	1.000
Hospitalized	23.5 (4)	24.1 (9)	

*No significant difference was observed. Sample size is too small to draw any decision.

Table S4: Whole genome sequence analysis among immunized and unimmunized group for the confirmation of SARS-CoV-2 variants.

WGS ID	Accession no	Vaccination history	Disease outcome	Variant	synonymous mutation	Non-synonymous mutation
w15	EPI_ISL_2350167	Completely immunized	Recovered	20B	14	7
w4	EPI_ISL_2348653	Partially Immunized	Death	SA (Beta V2)	36	11
w7	EPI_ISL_2348658	Partially Immunized	Recovered	SA (Beta V2)	32	22
w8	EPI_ISL_2348660	Partially Immunized	still weak	SA (Beta V2)	33	19
w9	EPI_ISL_2348661	Partially Immunized	still weak	SA (Beta V2)	28	21
w10	EPI_ISL_2348662	Partially Immunized	Recovered	NY (Eta)	35	13
w3	EPI_ISL_2349879	Partially Immunized	Recovered	20B	20	13
w12	EPI_ISL_2348664	Unimmunized	Recovered	SA (Beta V2)	20	22
w13	EPI_ISL_2349692	Unimmunized	Death	SA (Beta V2)	33	11
w6	EPI_ISL_2350142	Unimmunized	Recovered	SA (Beta V2)	30	20
w2	EPI_ISL_2348652	Unimmunized	Recovered	B.1.1.7 (Alpha V1)	24	34
w11	EPI_ISL_2348663	Unimmunized	Recovered	NY (Alpha V1)	30	22
w5	EPI_ISL_2349880	Unimmunized	Death	Conventional (Alpha V1)	32	22
w1	EPI_ISL_2348651	Unimmunized	still weak	20B	22	12

Figure S1:
Comparison of the length of hospitalization among the immunized (12%, n=5) and unimmunized (18%, n=12) severe SARS-COV-2 infected patients (p=0.383).

Figure S2: The differences of *N*-gene and *ORF1b*-gene cycle threshold values among immunized and unimmunized group during the detection of COVID-19 using RT-PCR kit. The unamplified gene products were considered with a CT value 45, the maximum cycle of the experiment. The independent mean t-test were performed for *N*-gene (p=0.026) and *ORF1* gene (p=0.052).